Indirect comparison of tongxinluo capsule and danshen dripping pill for angina pectoris: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 11, Issue 8, 2011, Pages 919-931

  Jia, Yong Liang ^a   Zhang, Shi Kai ^a   Bao, Fei Fei ^a   Huang, Fang Yi ^b   Leung, Siu Wai ^a,c  

^a University of Macau   (Macao)

^b UNIVERSITY OF MACAU   (Macao)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Angina pectoris; Danshen dripping pill; Meta analysis; Randomized controlled trial; Systematic review; Tongxinluo capsule

Indexed keywords

CHINESE DRUG; DANSHEN DRIPPING PILL; ISOSORBIDE DINITRATE; TONGXINLUO CAPSULE; UNCLASSIFIED DRUG;

ANGINA PECTORIS; DRUG EFFICACY; EFFECT SIZE; ELECTROCARDIOGRAPHY; HUMAN; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 80052165624     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Chinese source
2. Chinese source
3. Chinese source
4. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina summary article: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation, 2003, 107(1): 149-158
5. Chinese source
6. Chen WQ, Zhong L, Zhang L, et al. Chinese medicine Tongxinluo significantly lowers serum lipid levels and stabilizes vulnerable plaques in rabbit model. J Ethnopharmacol, 2009, 401(1): 103-110
7. Chinese source
8. Chinese source
9. Chinese source
10. Chinese source
11. Chinese source
12. Chinese source
13. Chinese source
14. Chinese source
15. Chinese source
16. Wu T, Harrison RA, Chen X, et al. Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. Cochrane Database Syst Rev, 2006, (4): CD004474
17. Chinese source
18. Chinese source
19. Chinese source
20. Song FJ, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysis. BMJ, 2003, 326(7387): 472
21. Numthavaj P, Thakkinstian A, Dejthevaporn C, et al. Corticosteroid and antiviral therapy for Bell's palsy: a network meta-analysis. BMC Neurology, 2011, 11: 1.
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17 (1): 1-12.
23. Higgins JTP, Green S. Cochrane handbook for systematic reviews of interventions. Wiley Online Library, 2008
24. Geha RS, Schneeberger E, Merler E, et al. Heterogeneity of acquired or common variable agammaglobulinemia. N Engl J Med, 1974, 291(1): 1-6
25. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet, 2003, 361(9369): 1581-1589.
26. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bulletin, 1945, 6: 80-83
27. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: Guidelines on choice of axis. J Clin Epidemiol, 2001, 54(10): 1046-1055
28. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med, 2004, 23(11): 1663-1682
29. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med, 2002, 21(11): 1559-1573
30. Chinese source
31. Chinese source
32. Chinese source
33. Chinese source
34. Chinese source
35. Chinese source
36. Chinese source
37. Chinese source
38. Chinese source
39. Chinese source
40. Chinese source
41. Chinese source
42. Chinese source
43. Chinese source
44. Chinese source
45. Chinese source
46. Chinese source
47. Chinese source
48. Chinese source
49. Chinese source
50. Chinese source
51. Chinese source
52. Chinese source
53. Chinese source
54. Chinese source
55. Chinese source
56. Chinese source
57. Chinese source
58. Chinese source
59. Chinese source
60. Chinese source
61. Chinese source
62. Chinese source
63. Chinese source
64. Chinese source
65. Chinese source
66. Chinese source
67. Chinese source
68. Chinese source
69. Chinese source
70. Chinese source
71. Chinese source
72. Chinese source
73. Chinese source
74. Chinese source
75. Chinese source
76. Chinese source
77. Chinese source
78. Chinese source
79. Chinese source
80. Chinese source
81. Chinese source
82. Chinese source
83. Chinese source
84. Chinese source
85. Chinese source
86. Chinese source
87. Chinese source
88. Chinese source
89. Chinese source
90. Chinese source
91. Chinese source
92. Chinese source
93. Chinese source
94. Chinese source
95. Wang D, Bakhai A. Clinical trials: a practical guide to design, analysis, and reporting. Remedica, 2006.
96. Wang G, Mao B, Xiong ZY, et al. The quality of reporting of randomized controlled trials of traditional Chinese medicine: a survey of 13 randomly selected journals from mainland China. Clin Ther, 2007, 29(7): 1456-1467
97. Zhang D, Yin P, Freemantle N, et al. An assessment of the quality of randomized controlled trials conducted in China. Trials, 2008, 9: 22
98. Wu TX, Li YP, Bian ZX, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials, 2009, 10: 46
99. Liu JP. Current status of RCTs in Traditional Medicine in China. Kampo Medicine, 2009, 60: 141
100. Chinese source
101. Berger RL. Remark AS R86 on algorithm AS 152, Cumulative hyper geometric probability. Appl Stat, 1991, 40(2): 374-375.
102. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109): 629-634
103. Sterne JAC, Egger M. Funnel plots for detecting bias in metaanalysis: Guidelines on choice of axis. J Clin Epidemiol, 2001, 54(10): 1046-1055.
104. Sterne JA, Egger M, Smith GD. Systematic review in health care: Investigating and dealing with publication and other bias in meta-analysis. BMJ, 2001, 323(7304): 101-105.